Codexis Inc's Suppliers recorded an increase in sales by 10.36 % year on year in Q2 2026, sequentially sales grew by 10.77 %, Codexis Inc recorded an increase in cost of sales by 67.4 % year on year, sequentially cost of sales grew by 70.16 % in Q2.
Codexis Inc's Suppliers recorded an increase in sales by 10.36 % year on year in Q2 2026, sequentially sales grew by 10.77 %, Codexis Inc recorded increase in cost of sales by 67.4 % year on year, sequentially cost of sales grew by 70.16 % in Q2.
The FDA regulatory process for drug and biologic products involves multiple stages before marketing in the U.S. These stages include preclinical testing, submission of an Investigational New Drug (IND) application, clinical trials, and submission of a New Drug Application (NDA) or Biologics License Application (BLA). The FDA conducts inspections to ensure compliance with current Good Manufacturing Practices (cGMP) before reviewing and approving the product. Post-approval, the FDA continues to regulate these products through requirements such as record-keeping, adverse event reporting, inspections, and strict controls on manufacturing changes. Failure to comply with FDA regulations can result in consequences including withdrawal of approval, product recalls, fines, and other enforcement actions. The process also encompasses supplier qualification and adherence to customer contracts and specifications.
Codexis Inc's Comment on Supply Chain
The FDA regulatory process for drug and biologic products involves multiple stages before marketing in the U.S. These stages include preclinical testing, submission of an Investigational New Drug (IND) application, clinical trials, and submission of a New Drug Application (NDA) or Biologics License Application (BLA). The FDA conducts inspections to ensure compliance with current Good Manufacturing Practices (cGMP) before reviewing and approving the product. Post-approval, the FDA continues to regulate these products through requirements such as record-keeping, adverse event reporting, inspections, and strict controls on manufacturing changes. Failure to comply with FDA regulations can result in consequences including withdrawal of approval, product recalls, fines, and other enforcement actions. The process also encompasses supplier qualification and adherence to customer contracts and specifications.
CDXS's Suppliers Net profit fell by
CDXS's Suppliers Net margin fell in Q2 to
-2.25 %
9.73 %
CDXS's Suppliers Net profit fell by -2.25 %
CDXS's Suppliers Net margin fell in Q2 to 9.73 %
Codexis Inc's Suppliers Sales Growth
in Q2 2026 by Industry
Sources:
Codexis inc 's official press releases and regulatory filings; CSIMarket.com's supply-chain research; and the financial filings and press releases of other companies cited in this report.
Updated on:
For your research, we’ve provided nine additional tables on Codexis inc ’s suppliers.
You can find them in the navigation menu under Suppliers.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
7.74 %